This criterion opens Core Function V, Preparation, and it is the first criterion in the workbook that asks the facilitator to develop individualized support for a client's physical preparation. That planning carries a scope hazard the assessment criteria did not, because some physical-preparation guidance sits squarely within a facilitator's lane and some belongs to a physician. The module draws that line explicitly. The pharmacological hazards touched here, dietary tyramine related hypertension, serotonin toxicity from relevant drug combinations, and other cardiovascular or metabolic interactions, are separated by mechanism and coordinated with the clinical review taught in Criteria 1 and 2, and the medication-tapering question is treated as the medical decision it is.
Learning Objectives
By the end of this module, the trainee will be able to:
- Explain why physical preparation bears on both the safety and the receptivity of psychedelic work.
- Develop an individualized physical-preparation plan across diet, exercise, and sleep, matched to the client's baseline rather than a generic protocol.
- Distinguish tyramine related hypertensive interactions from serotonin toxicity drug interactions and other cardiovascular or metabolic interactions with relevant MAO inhibition; connect each to the compound specific review in Criterion 2.
- State accurately what is and is not known about antidepressant interactions with psychedelics, and treat medication tapering as a medical decision referred to a prescriber.
- Draw the scope line between physical-preparation guidance a facilitator may give and medical management that must be referred out.
- Give sleep-hygiene guidance grounded in established practice, and recognize when sleep problems warrant professional referral.
- Frame exercise recommendations at the level the evidence supports, favoring balance and the client's baseline over prescription.
- Deliver physical-preparation guidance in a supportive, non-judgmental way, especially around substance use.
Key Terms
Physical preparation. The optimization of the client's bodily condition, across diet, exercise, sleep, and substance use, in the weeks before a session, to support both safety and receptivity.
Receptivity. The body's readiness to enter, sustain, and recover from an altered state. A rested, nourished, stable body tolerates the physiological demands of the experience more easily.
Dietary interaction. A food and drug interaction relevant to the specific preparation. Tyramine with clinically meaningful MAO inhibition can increase catecholaminergic activity and blood pressure; this is distinct from serotonin toxicity. Ayahuasca’s reversible harmala inhibition should not be assigned the magnitude or duration of irreversible pharmaceutical MAO inhibition (Ruffell et al., 2020).
Tyramine. A monoamine found in some aged, fermented, and cured foods. When relevant MAO inhibition reduces its metabolism, increased tyramine exposure can promote catecholamine release and a hypertensive reaction. Risk depends on the MAOI, inhibition, and exposure. Dietary precautions require preparation specific medical guidance (Ruffell et al., 2020).
Sleep hygiene. The set of behavioral practices that support consistent, adequate sleep: regular sleep and wake times, a wind-down routine, limiting screens and evening stimulants, and a suitable sleep environment.
Scope of practice. The boundary between guidance a facilitator is competent and authorized to give (general diet, movement, and sleep-hygiene education) and decisions that belong to a physician (managing hypertension, tapering prescribed medication).
Medication tapering. The supervised reduction or discontinuation of a prescribed medication. For psychiatric medications this is a medical decision made with the prescriber, never advised by a facilitator, because abrupt discontinuation carries its own risks.
Non-judgmental stance. The disposition required when discussing substance use and lifestyle, which makes honest disclosure and genuine change more likely than instruction delivered as correction.
Core Teaching
Why the body is part of preparation
Preparation begins in the body, weeks before the medicine. A psychedelic session places real demands on the cardiovascular system, emotional regulation, and the capacity to recover, and the condition a person arrives in shapes how those demands are met. The rationale for physical preparation rests on two concerns that run through the whole criterion. The first is safety. Certain physical states, such as uncontrolled high blood pressure, cardiovascular strain, and chronic sleep deprivation, raise the probability of an adverse event during a session, and some of them are the same states the screening of Criteria 1 through 3 was built to catch. The second is receptivity. The body is the instrument through which the experience is metabolized, and a rested, nourished, stable body tends to enter, sustain, and recover from an altered state more smoothly than a depleted one. Physical preparation simultaneously addresses both aspects and has an additional, subtler effect: the process of preparing the body serves as a form of engagement. It allows the client to start the work before the session, which many practitioners notice can alter their perception of what's ahead.
A theme from harm-reduction practice grounds this. In field settings, a large share of acute crises trace less to the substance than to the state of the body carrying it: exhaustion, dehydration, undernourishment, and lack of sleep. The same variables, corrected in advance, are often what separates a manageable experience from a destabilizing one. Physical preparation is the deliberate, unglamorous work of removing those avoidable risks before they compound.
Diet and clinically important MAO interactions
Dietary guidance divides into the generally beneficial and the genuinely safety-critical, and the two should not be confused. On the general side, guidance toward whole foods, adequate hydration, and moderation of caffeine and alcohol in the days before a session is low-risk, supportive advice within a facilitator's lane, and heavy or highly processed meals close to a session commonly worsen the nausea that several medicines already provoke. Many programs use a simplified eating plan in the days beforehand, and in research settings a defined fasting window before dosing is standard.
Ayahuasca contains harmala alkaloids that reversibly inhibit monoamine oxidase A. Three interaction domains need separate explanations. First, tyramine with clinically meaningful MAO inhibition is principally a catecholaminergic hypertensive mechanism, not serotonin toxicity. Second, MAO inhibition with SSRIs, SNRIs, MDMA, tramadol, or other substantial serotonin releasing or reuptake inhibiting agents can increase serotonin toxicity risk. Direct receptor agonists must not automatically inherit this mechanism. Third, sympathomimetic drugs, altered metabolism, cardiovascular effects, and other medications introduce additional mechanisms that require their own review. Ruffell and colleagues (2020) describe lower tyramine interaction risk with reversible MAO-A inhibition than irreversible nonselective inhibition, alongside major gaps in ayahuasca interaction research. Traditional preparations vary in composition and exposure and do not necessarily produce the same magnitude or duration of inhibition as irreversible pharmaceutical MAOIs. The available review does not establish a quantified fatal dietary tyramine risk for ayahuasca; it also does not justify ignoring food interactions. Distinguish medically indicated dietary precautions from cultural practices, review the particular preparation and person with qualified medical expertise, and obtain a complete medication and supplement history. A facilitator explains and coordinates; appropriately qualified clinicians determine medical dietary and prescription management.
The medication question
Antidepressant interactions require drug specific interpretation. In a controlled crossover study in healthy volunteers, short escitalopram pretreatment did not reduce positive mood effects of psilocybin and reduced some anxiety and adverse effects (Becker et al., 2022). This does not represent every SSRI, long term treatment, or clinical population. A small open label study administered psilocybin while patients continued an SSRI; it cannot establish general safety or comparative efficacy (Goodwin et al., 2023). Receptor adaptation is a possible pharmacodynamic explanation for altered response, not a demonstrated uniform mechanism or a pharmacokinetic effect. Erritzoe et al. (2024) analyzed antidepressant discontinuation retrospectively within a trial; the exploratory comparison cannot establish that discontinuation caused outcome differences. Current SSRI treatment is not a universal requirement for discontinuation before psilocybin. The prescriber and appropriately qualified psychedelic medicine clinician consider indication, stability, duration, withdrawal risk, the specific drugs, and the setting. This conclusion does not extend to SSRI use with MAOI containing ayahuasca.
The scope consequence is firm and non-negotiable. Tapering or discontinuing a psychiatric medication is a medical decision made with the prescribing clinician, and it is never something a facilitator advises or manages. Abrupt discontinuation of an antidepressant carries its own risks, including discontinuation syndrome and the return of the condition the medication was treating. A facilitator's role in physical preparation is to know that these interactions exist, to raise them, and to route every medication question to the client's prescriber or the program's medical professional. A facilitator who tells a client to stop their medication has stepped outside their scope and into a decision that can cause serious harm.
Exercise, at the level the evidence supports
Physical activity during the preparation period should be framed modestly, as the broad claims often exaggerate its benefits. Light to moderate activities like walking, gentle yoga, swimming, and stretching are reasonable guidelines. These are especially sensible for clients who will remain lying still for long periods during a session. The honest goal is to achieve a balance tailored to the individual's baseline, not a fixed regimen. Someone who trains intensively may benefit from easing up before a session, while a sedentary person might do well with daily walks. Claims that exercise reliably reduces stress or that overtraining weakens immunity around a session are often overstated, so this module advocates for the core recommendation: gentle, regular movement suited to the individual, without prescribing intensity beyond the facilitator's scope. Having a proper balance is the goal, always.
Sleep, the most overlooked preparation
Sleep is the preparation variable clients most often neglect and one of the most consequential, because inadequate sleep degrades emotional regulation and raises baseline anxiety, both of which bear directly on how a person weathers an intense experience. Sleep-hygiene guidance is squarely within a facilitator's lane and worth giving concretely: consistent sleep and wake times, a wind-down routine, limiting screens before bed, keeping the bedroom cool and dark, and avoiding caffeine and other stimulants late in the day. Where a client's sleep is genuinely disordered, chronic insomnia, or sleep disruption tied to a condition such as sleep apnea or a mood disorder, the appropriate move is referral rather than more sleep-hygiene tips, because disordered sleep can be a medical matter. Helping a client track their sleep across the preparation weeks makes the guidance concrete and surfaces problems that warrant a professional.
Substance use, handled without judgment
Reducing alcohol and recreational substances in the preparation window is sound guidance, both because some substances raise cardiovascular or interaction risk and because entering the work with a clearer baseline supports receptivity. The manner of the conversation matters as much as the content, because many clients arrive with entrenched patterns and a history of being lectured about them. Ask without judgment and explain why the information matters. A respectful conversation can address barriers to disclosure, but its tone does not establish complete reporting or predict durable change. Sudden cessation can be dangerous when alcohol dependence is present; confusion or other severe withdrawal symptoms require urgent care. Where substance use reaches the level of dependence, or where prescription medications are involved, the facilitator coordinates with a medical professional rather than managing a taper themselves, for the same scope reasons that govern the medication question above. The line throughout this criterion is consistent: a facilitator educates, supports, and refers, and does not practice medicine.
Clinical and Decision Tools
Tool 1. The four areas of physical preparation
What to address in each area, and where the facilitator's lane ends. The shaded row is safety-critical and its pharmacology lives in Criteria 1 and 2.
Area | Facilitator guidance (in scope) | Refer to a professional when |
|---|---|---|
Diet (general) | Whole foods, hydration, moderate caffeine/alcohol, light pre-session eating | A medical condition constrains diet |
Diet (ayahuasca) | Explain potential food interactions; obtain substance-specific medical dietary guidance | Preparation specific dietary uncertainty, cardiovascular concerns, or interacting drugs: obtain qualified medical review. Tyramine hypertension and serotonin toxicity require separate reasoning. |
Exercise | Gentle, regular movement matched to baseline | Cardiac or orthopedic limits apply |
Sleep | Sleep-hygiene education; sleep tracking | Chronic insomnia or suspected sleep disorder |
Substance use | Non-judgmental reduction guidance | Dependence, or any prescribed medication taper |
Tool 2. The scope line in physical preparation
The consistent rule: educate, support, and refer; do not practice medicine. Shaded rows are outside a facilitator's scope.
Action | In a facilitator's scope? |
|---|---|
General diet, hydration, and pre-session eating guidance | Yes |
Sleep-hygiene education and sleep tracking | Yes |
Gentle movement recommendations matched to baseline | Yes |
Explaining that medication interactions exist and raising them | Yes |
Advising a client to stop or taper a psychiatric medication | No: prescriber decides |
Managing hypertension or a cardiac condition | No: physician |
Interpreting whether a client is medically cleared | No: physician |
Tool 3. Individualizing to baseline
Physical preparation is matched to the person, not applied uniformly. Assess baseline first, then calibrate.
Client baseline | Calibration |
|---|---|
Trains hard daily | Ease intensity in the final days; avoid depletion |
Sedentary | Add a daily walk; keep it gentle and achievable |
Poor sleep | Concrete sleep-hygiene plan; track; refer if disordered |
Hypertension or cardiac history | Physician-led; facilitator does not manage this |
Entrenched substance use | Non-judgmental reduction; medical coordination if dependent |
Tool 4. Physical-preparation plan checklist
Confirm the plan is individualized, safe, and within scope. Shaded items are the safety-critical and scope checks.
Check | Done? |
|---|---|
Baseline activity, diet, sleep, and substance use assessed | Yes / No |
Recommendations matched to this client, not a generic protocol | Yes / No |
Ayahuasca ingredients and dietary precautions reviewed with a qualified medical professional | Yes / No |
All medication questions routed to a prescriber, none advised by facilitator | Yes / No |
Sleep problems beyond hygiene referred appropriately | Yes / No |
Substance-use conversation held without judgment | Yes / No |
Nothing in the plan practices medicine outside the facilitator's scope | Yes / No |
Worked Example: A Physical-Preparation Plan
The following models an individualized plan that stays within scope and treats the medication question correctly. Details are fictional.
Client and context: A 54-year-old client preparing for a psilocybin session, mildly hypertensive, on a daily SSRI, sedentary, average sleep, moderate evening alcohol. Seen at a clinically supervised program with prescriber access.
Diet: Guidance toward whole foods, hydration, and reduced caffeine and alcohol in the two weeks prior; light eating on the day per the program's protocol. Low-risk, in scope.
The medication and blood pressure, referred: The SSRI and the hypertension are flagged and routed to the prescriber and program physician. The facilitator does not advise tapering the SSRI and does not manage the blood pressure; they document the referral and await medical guidance before finalizing the plan.
Exercise: A daily twenty-minute walk introduced gently, matched to a sedentary baseline, with no intensity prescription. Framed as supportive, not mandatory.
Sleep: Concrete sleep-hygiene plan (consistent times, screen limit, no late caffeine) and a two-week sleep log. If the log reveals genuine insomnia, referral rather than more tips.
Substance use: A non-judgmental conversation about the evening alcohol, framed around the client's own safety and goals, with a suggested reduction. No lecturing.
Result: An individualized plan in which every in-scope element is addressed and every medical element (SSRI, hypertension) is referred. The plan is finalized only after the prescriber weighs in.
Case Vignettes
Work each vignette by identifying the error, the principle at stake, and the correct handling. Fillable response sheets are in the companion worksheet PDF.
Vignette A
A facilitator, aware that antidepressants can interact with psilocybin, tells a client to stop taking their SSRI two weeks before the session so the medicine will work better. The client stops abruptly and experiences discontinuation symptoms and a return of depression.
Guided questions: What scope line did the facilitator cross, and why is it dangerous? What does the actual evidence say about SSRI interactions? How should the medication question have been handled?
Vignette B
A facilitator preparing a client for an ayahuasca retreat gives general wellness advice but never addresses the dietary restriction, and the client eats aged cheese and cured meats the day before.
Guided questions: What safety-critical interaction was missed, and what is its mechanism? How does it connect to Criteria 1 and 2? What must an ayahuasca preparation plan always include, and what medication question must be asked?
Vignette C
A facilitator gives every client the same preparation plan: an hour of vigorous exercise daily, a strict diet, and a fixed sleep schedule. A sedentary 60-year-old client with a cardiac history is told to begin daily high-intensity workouts.
Guided questions: What is wrong with a one-size-fits-all plan? Which element here is actively unsafe, and whose decision should it have been? How should the plan have been individualized to baseline?
Vignette D
A client discloses heavy daily drinking during the preparation conversation. The facilitator responds with visible disapproval and a lecture about health, and the client, embarrassed, stops disclosing and conceals the true extent of their use.
Guided questions: What did the judgmental response cost in terms of safety information? How should a substance-use conversation be conducted? At what point does substance use require medical coordination rather than facilitator guidance?
Vignette E
A facilitator notices a client's blood pressure readings are high during preparation and, wanting to be helpful, suggests specific supplements and dietary changes to lower it, without involving a physician.
Guided questions: Where did the facilitator step outside their scope? Why is managing hypertension a physician's role? What was the appropriate action on noticing the high readings?
Role-Play and Practice Scripts
Practice in pairs, then switch. The aim is to give physical-preparation guidance that is individualized, supportive, and strictly within scope.
Raising the medication question without overstepping
“I see you are on an antidepressant. That is important, and I want to be clear about how we handle it. I am not the person who makes any decision about your medication, and you should not change it on your own. What we will do is loop in the prescriber so that the decision is made safely by someone qualified. My job is to make sure it gets asked, not to answer it.” Practice raising and routing, without advising.
Explaining the ayahuasca dietary restriction
“This brew can interact with medicines and may require dietary precautions. The risks depend on its ingredients and your health history. We will ask a qualified medical professional to review the preparation guidance, along with every medication and supplement you take.” Practice explaining the uncertainty clearly without treating a traditional diet as a substitute for medical review.
A non-judgmental substance-use conversation
“I want to ask about alcohol and any other substances, and I want to do it straight and without judgment. I am not here to grade you. I ask because it affects your safety and what you will get out of this work. Tell me honestly what your use looks like, and we will figure out a sensible plan together.” Practice a tone that invites honesty rather than concealment.
Individualizing to baseline
“Before I suggest anything about movement or sleep, tell me where you are starting from. What does a normal week of activity look like for you, and how are you sleeping? I would rather build something realistic for your life than hand you a generic plan you will not keep.” Practice assessing baseline before recommending.
Self-Assessment and Reflection
Knowledge check
- Explain the two concerns, safety and receptivity, that justify physical preparation.
- Explain the potential tyramine interaction with ayahuasca, how reversible MAO-A inhibition differs from irreversible MAO inhibition, and why dietary and medication guidance require medical review.
- State accurately what is known about SSRI interactions with psilocybin, including the escitalopram trial finding, and explain why medication tapering is out of scope.
- Draw the scope line: give two physical-preparation actions in a facilitator's lane and two that must be referred.
- Explain how to individualize a plan to a client's baseline, with an example for a sedentary client and a highly trained one.
- Give the core elements of sleep-hygiene guidance and name when a sleep problem warrants referral.
- Explain why a non-judgmental stance on substance use is a safety matter, not only a courtesy.
Reflection
- Where might you be tempted to give medical advice, on medication, blood pressure, or supplements, that actually belongs to a physician? What will keep you on the right side of that line?
- How thoroughly do you assess a client's baseline before making physical-preparation recommendations, and where could a generic plan have done harm?
- How do you handle substance-use conversations? Is your manner producing honest disclosure or quiet concealment?
Summary
Criterion 16 opens Core Function V by asking the facilitator to develop an individualized plan for physical preparation across diet, exercise, and sleep. It is the first criterion to make prescriptive recommendations about the client's body, introducing a scope hazard the assessment criteria did not address. Physical preparation serves two ends, safety and receptivity, and is grounded in harm reduction: exhaustion, dehydration, undernourishment, and poor sleep may create avoidable concerns that deserve assessment alongside compound specific hazards. This does not establish that preparation removes drug risk or that these factors cause most crises. Dietary preparation distinguishes cultural practices from medical precautions; reversible MAO-A inhibition in ayahuasca should not be equated with irreversible MAOI dietary risk, and substance-specific guidance requires medical review (Ruffell et al., 2020). Tyramine related hypertensive risk is catecholaminergic and distinct from serotonin toxicity; sympathomimetic burden, metabolism, and other cardiovascular interactions require separate review. The medication question is stated honestly: antidepressant interactions with psychedelics are real, drug-specific, and incompletely understood; escitalopram pretreatment did not blunt psilocybin's positive effects in a controlled trial (Becker et al., 2022); the discontinuation question is unresolved (Erritzoe et al., 2024); and tapering a psychiatric medication is a medical decision made with the prescriber and never advised by a facilitator. Exercise guidance is kept to the defensible core of gentle, regular movement matched to baseline. Sleep-hygiene education is squarely in scope, with referral where sleep is genuinely disordered. Substance-use guidance is delivered without judgment, because manner determines whether the client discloses honestly. The line running through the criterion is consistent: a facilitator educates, supports, and refers, and does not practice medicine.
References
Becker, A. M., Holze, F., Grandinetti, T., Klaiber, A., Toedtli, V. E., Kolaczynska, K. E., Duthaler, U., Varghese, N., Eckert, A., Grünblatt, E., & Liechti, M. E. (2022). Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Clinical Pharmacology & Therapeutics, 111(4), 886–895. https://doi.org/10.1002/cpt.2487
Erritzoe, D., Barba, T., Spriggs, M. J., Rosas, F. E., Nutt, D. J., & Carhart-Harris, R. (2024). Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression. Journal of Psychopharmacology, 38(5), 458–470. https://doi.org/10.1177/02698811241237870
Ruffell, S., Netzband, N., Bird, C., Young, A. H., & Juruena, M. F. (2020). The pharmacological interaction of compounds in ayahuasca: A systematic review. Brazilian Journal of Psychiatry, 42(6), 646–656. https://doi.org/10.1590/1516-4446-2020-0884
Halman, A., Kong, G., Sarris, J., & Perkins, D. (2024). Drug–drug interactions involving classic psychedelics: A systematic review. Journal of Psychopharmacology, 38(1), 3–18. https://doi.org/10.1177/02698811231211219
Goodwin, G. M., et al. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology, 48, 1492–1499. https://doi.org/10.1038/s41386-023-01648-7

